Research programme: alcoholism therapeutics - ADial Pharmaceuticals

Drug Profile

Research programme: alcoholism therapeutics - ADial Pharmaceuticals

Alternative Names: Naltrexone/ondansetron/topiramate; Naltrexone/topiramate; Naltrexone/topiramate/ondansetron; Ondansetron/naltrexone/topiramate; Ondansetron/topiramate/naltrexone; Topiramate/naltrexone; Topiramate/naltrexone/ondansetron; Topiramate/ondansetron/naltrexone

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ADial Pharmaceuticals
  • Class Carbazoles; Hexoses; Imidazoles; Ketoses; Morphinans; Small molecules; Sulfonic acids
  • Mechanism of Action AMPA receptor antagonists; Carbonic anhydrase inhibitors; GABA A receptor agonists; Kainic acid receptor antagonists; Opioid receptor antagonists; Serotonin 3 receptor antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Alcoholism

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alcoholism in USA
  • 01 Apr 2013 Preclinical trials in Alcoholism in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top